| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Letters to the Editor |
aPediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA; bLombardi Comprehensive Cancer Center, Georgetown University School of Medicine, Washington, DC, USA
Key Words. IGF-1R • Pediatric malignancy • Molecular targeting • Therapeutic antibody
Correspondence: Correspondence: Su Young Kim, M.D., Ph.D., Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, 10 Center Drive, Building 10, CRC 1w-3750, Bethesda, Maryland 20892, USA. Telephone: 301-451-7018; Fax: 301-451-7010; e-mail: kimsuyou{at}mail.nih.gov
Received August 22, 2008; accepted for publication December 1, 2008.
Disclosure: The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias. No financial relationships relevant to the content of this article have been disclosed by the authors, planners, independent peer reviewers, or staff managers.
The insulin-like growth factor (IGF) family consists of ligands (IGF-I, IGF-II, insulin), several receptors (including IGF-1R), and six binding proteins (IGFBP-1 through IGFBP-6). Members of this family regulate key cellular activities and they also play an important role in the development and progression of both adult and childhood cancers. Binding of a ligand to the receptor leads to its activation, followed by signal transduction along several pathways. In some childhood malignancies, IGF-1R can be activated by endocrine, autocrine, or paracrine mechanisms. Although mutations in IGF-1R have not been identified, this signaling pathway is upregulated in many childhood cancers. These findings have led to the development of a host of IGF-1R signaling modulators that are currently being tested in clinical trials. This review explores the role of IGF-1R in a range of childhood malignancies.
This article has been cited by other articles:
![]() |
Z. Duan, E. Choy, D. Harmon, C. Yang, K. Ryu, J. Schwab, H. Mankin, and F. J. Hornicek Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines Mol. Cancer Ther., August 1, 2009; 8(8): 2122 - 2130. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| THE ONCOLOGIST | STEM CELLS | CME | ALPHAMED PRESS JOURNALS |